Soleno Therapeutics, Inc. (SLNO)
| Previous close | 0.1768 |
| Open | 0.1795 |
| Bid | 0.1922 x 900 |
| Ask | 0.1950 x 1000 |
| Day's range | 0.1759 - 0.2000 |
| 52-week range | 0.1300 - 1.6700 |
| Volume | |
| Avg. volume | 781,228 |
| Market cap | 15.427M |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, virtually and in Miami, FL. The presentation will be available on-demand beginning at 7 AM Eastern
- GlobeNewswire
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three months ended March 31, 2022. First Quarter 2022 and Recent Corporate Highlights Continuing dialogue with the U.S. Food and Drug Administration (FDA) to obtain alignment on the design of a study to provid
- GlobeNewswire
Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome
Results Show Significant Improvements in Hyperphagia and PWS-Related Behaviors in DCCR-Treated Patients Presentations at the Pediatric Academic Societies 2022 Virtual Annual Meeting and Pediatric Endocrinology Society 2022 Virtual Annual Meeting REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced two presentations hig
